$1.84
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
INmune Bio Says Study Shows Drug Candidate Reduced Alzheimer's-Related Brain Changes After Brain Injury
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
Overview
52-week range
$1.09
$12
7% of range
Avg surprise (last 2)
+4.1%
Avg reaction (last 2)
-3.3%
0% positive
Latest IV / EM
83%
EM ±19.0% · $2 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.20 | — | — | +53.5% | -5.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.24 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.34 | $-0.37 | +8.1% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.43 | $-0.43 | 0.0% | — | -0.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.60 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.50 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.61 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.48 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.36 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | — | -$0.34 |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $50,000 | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-6M | — | $-7M | $-25M | $-10M | — | $-12M | $-10M |
| Net income | $-5M | — | $-6M | $-24M | $-10M | — | $-12M | $-10M |
| EPS (diluted) | $-0.20 | — | $-0.24 | $-1.05 | $-0.43 | — | $-0.60 | $-0.50 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | $28M | $33M | $19M | $21M | $34M | $31M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $23M | $30M | $31M | $36M | $21M | $23M | $36M | $35M |
| Total assets | $26M | $32M | $33M | $38M | $38M | $40M | $53M | $52M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $6M | $9M | $8M | $9M | $8M | $7M | $14M | $15M |
| Total equity | $20M | $24M | $25M | $29M | $30M | $32M | $39M | $36M |